# Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy

> **NCT02470039** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 50 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin 338 (GIPET I)
- **DRUG:** insulin glargine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02470039
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-01
- **Primary completion:** 2015-12-31
- **Final completion:** 2015-12-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02470039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02470039, "Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02470039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*